<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04242706</url>
  </required_header>
  <id_info>
    <org_study_id>PL-13674</org_study_id>
    <nct_id>NCT04242706</nct_id>
  </id_info>
  <brief_title>VITAL - VAP Prevention by BIP (Bactiguard Infection Protection) ETT Evac in Belgian ICUs</brief_title>
  <acronym>VITAL</acronym>
  <official_title>VITAL - VAP Prevention in ICU by BACTIGUARD coAting of endotracheaL Tube</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bactiguard AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bactiguard AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to determine VAP (Ventilator Associated Pneumonia) baseline incidence&#xD;
      in the ICU in patients receiving endotracheal tubes with evacuation lumen with and without&#xD;
      Bactiguard coating. The study is randomized, prospective, controlled and blinded. All adult&#xD;
      patients hospitalized in the ICUs from two tertiary hospitals (i.e.: Centre Hospitalier&#xD;
      Universitaire Sart Tilman Liège , Centre Hospitalier Chrétien de Liège) and considered to be&#xD;
      ventilated for more than 24 hours will be eligible to participate in the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to determine VAP (Ventilator Associated Pneumonia) baseline incidence&#xD;
      in the ICU in patients receiving endotracheal tubes with evacuation lumen with and without&#xD;
      Bactiguard Infection Protection (BIP) coating.&#xD;
&#xD;
      VAP is likely to occur in 10-20% of patients who are ventilated for at least 48 hours. These&#xD;
      patients face a mortality risk estimated to be twice as high compared with similar ICU&#xD;
      patients without VAP. Furthermore, VAP results in an average excess length of ICU stay with&#xD;
      high hospital cost.&#xD;
&#xD;
      Bactiguard has developed an endotracheal tube coated with a thin layer of non-releasing&#xD;
      metals (gold, silver and palladium) firmly attached to the surface. This Bactiguard coating&#xD;
      is tissue friendly and aims to achieve an optimal combination of anti-infective properties to&#xD;
      reduce biofilm formation, colonization and subsequent respiratory infection. Bactiguard&#xD;
      coated urinary products have been on market since 1995 (initially in US, then also in Japan &amp;&#xD;
      Europe) and used in a large number of clinical studies and evaluations, showing reduction of&#xD;
      urinary tract infections and also antibiotics use. A BIP ETT (without evacuation lumen)&#xD;
      clinical safety and tolerability study was performed at Karolinska University Hospital during&#xD;
      20128. The study showed that BIP ETT is safe, well tolerable and performs well in clinical&#xD;
      settings.&#xD;
&#xD;
      The present study of BIP ETT with evacuation lumen is randomized, prospective, controlled and&#xD;
      blinded. All adult ICU patients hospitalized in the ICUs from two tertiary hospitals (i.e.:&#xD;
      Centre Hospitalier Universitaire Sart Tilman Liège , Centre Hospitalier Chrétien de Liège)&#xD;
      and considered to be ventilated for more than 24 hours will be eligible to participate in the&#xD;
      study. 300 patients in total will be used to determine baselines levels (150 in each group).&#xD;
&#xD;
      The study tubes will be available not only in the ICUs but also in the emergency department,&#xD;
      including the emergency vehicles, and in every hospital wards. The study tubes will not be&#xD;
      available in the operating rooms except in the Post Anesthesia Care Units (PACU) and Recovery&#xD;
      rooms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 31, 2018</start_date>
  <completion_date type="Actual">May 8, 2020</completion_date>
  <primary_completion_date type="Actual">May 8, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Controlled study. Two interventions:&#xD;
Endotracheal tube with evacuation lumen without Bactiguard coating.&#xD;
Endotracheal tube with evacuation lumen with Bactiguard coating.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Blinded, the two devices have the same appearance.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>VAP incidence</measure>
    <time_frame>Up to 28 days after inclusion</time_frame>
    <description>Ventilator Associated Pneumonia incidence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nosocomial infections</measure>
    <time_frame>Up to 28 days after inclusion</time_frame>
    <description>Incidence of any kind of nosocomial infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAT incidence</measure>
    <time_frame>Up to 28 days after inclusion</time_frame>
    <description>Ventilator Associated Tracheabronchitis incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotics consumption</measure>
    <time_frame>Up to 28 days after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ventilation</measure>
    <time_frame>Up to 28 days after inclusion</time_frame>
    <description>Days of intubation with study tube</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU and hospital stay</measure>
    <time_frame>Up to 28 days after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 60 days after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tracheal bacterial colonization</measure>
    <time_frame>Up to 28 days after inclusion</time_frame>
    <description>Incidence of tracheal bacterial colonization reaching a CFU Count 10^6 CFU/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAC and iVAC</measure>
    <time_frame>Up to 28 days after inclusion</time_frame>
    <description>Ventilator associated Condition and infectious iVAC</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of microbial data</measure>
    <time_frame>Up to 28 days of intubation after inclusion</time_frame>
    <description>Amount and type of bacteria, resistance pattern</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of durability of the coating metals at the surface during use</measure>
    <time_frame>Up to 28 days of intubation after inclusion</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">323</enrollment>
  <condition>Ventilator-associated Pneumonia</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endotracheal tube with evacuation lumen without Bactiguard coating.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endotracheal tube with evacuation lumen with Bactiguard coating.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ETTEvac</intervention_name>
    <description>Endotracheal tube with evacuation lumen without noble metal coating</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BIP ETTEvac</intervention_name>
    <description>Endotracheal tube with evacuation lumen with noble metal coating</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  intubation with a study tube and a presumed duration of ventilation for more than 24h,&#xD;
&#xD;
          -  age &gt; 18 y,&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  tracheostomized patient&#xD;
&#xD;
          -  life expectancy less than 48h,&#xD;
&#xD;
          -  previous participation in the study&#xD;
&#xD;
          -  pregnant women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Misset, MD,Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU, Liege; Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Chrétien de Liège and Centre Hospitalier Chrétien (CHC Clinique de l'Espérance)</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Sart Tilman Liège</name>
      <address>
        <city>Liège</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 13, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

